Previous 10 | Next 10 |
LITTLETON, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (NASDAQ: VVOS) (“Vivos” or “the Company”), a revenue-generating medical technology company focused on developing innovative treatments for patients suffering from dentofacia...
Gainers: Avadel Pharmaceuticals (AVDL) +123%. SIGA Technologies (SIGA) +40%. Concert Pharmaceuticals (CNCE) +30%. Farfetch (FTCH) +25%. Allarity Therapeutics (ALLR) +25%. Merus N.V. (MRUS) +23%. Tenon Medical (TNON) +22%. Arcturus Therapeutics Holdings (ARCT) +19%. Red Rob...
Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, will ...
HIGHLANDS RANCH, Colo., May 26, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (NASDAQ: VVOS) (“Vivos” or the “Company”), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalit...
Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea ("OSA") and snoring in adults, is ...
Vivos Therapeutics, Inc. (VVOS) Q1 2022 Earnings Conference Call May 16, 2022 05:00 p.m. ET Company Representatives Kirk Huntsman - Chairman, Chief Executive Officer Brad Amman - Chief Financial Officer Julie Gannon - Investor Relations Officer Conference Call Participants Alex Nowak - Craig-...
Vivos Therapeutics press release (NASDAQ:VVOS): Q1 GAAP EPS of -$0.26 in-line. Revenue of $3.46M (+0.3% Y/Y) misses by $0.98M. For further details see: Vivos Therapeutics GAAP EPS of -$0.26 in-line, revenue of $3.46M misses by $0.98M
First Quarter Appliance Revenue Increased 19% Year-Over-Year Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., May 16, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or the “Company'') (NASDAQ: VVOS...
Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snorin...
HIGHLANDS RANCH, Colo., April 28, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities ...
News, Short Squeeze, Breakout and More Instantly...
Vivos Therapeutics Inc. Company Name:
VVOS Stock Symbol:
NASDAQ Market:
Vivos Therapeutics Inc. Website:
LITTLETON, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company” (NASDAQ:VVOS) , a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments f...
Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) i...
Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos’ Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit Private Placement Investment Sponsored by Seneca Partners, Who Will Also Provide General Management Advisory ...